NCT06860971 A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma
| NCT ID | NCT06860971 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Condition | Thyroid Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 144 participants |
| Start Date | 2025-04-18 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 144 participants in total. It began in 2025-04-18 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to demonstrate that, in subjects with locally advanced or metastatic iodine - refractory differentiated thyroid cancer who have failed previous VEGFR - targeted therapy, AL2846 can significantly prolong progression - free survival (PFS) compared with placebo.
Eligibility Criteria
Inclusion Criteria: * Participants voluntarily join the study, sign the informed consent form, and demonstrate good compliance. * Histologically or cytologically confirmed locally advanced or metastatic differentiated thyroid carcinoma (DTC). * Age: 18 years ≤ age \<75 years (calculated based on the date of signing the informed consent form). * Eastern Cooperative Oncology Group (ECOG) performance status score: 0-1. * Anticipated survival \>12 weeks. * At least one measurable lesion confirmed by RECIST 1.1 criteria. * Disease progression (per RECIST 1.1) after receiving no more than 2 lines (no more than 3 types) lines of Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR TKI) therapy * Confirmed iodine-refractory status, defined by \*\*one or more\*\* of the following: 1. Lesions show no iodine uptake on post-Iodine-131 therapy whole-body scan and are unlikely to benefit from further Iodine-131 therapy. 2. Previously iodine-avid lesions progressively lose iodine uptake after Iodine-131 therapy. 3. Mixed iodine-avid and non-iodine-avid lesions in the same patient with no biochemical response. 4. Iodine-avid lesions with disease progression (radiologically confirmed) within 12 months. 5. Cumulative Iodine-131 dose ≥600 mCi (22 GBq) with no disease response (radiologically confirmed). * Thyroid stimulating hormone (TSH) ≤0.5 mIU/L under TSH-suppressive therapy. * Laboratory parameters meeting the following criteria: 1. Hemoglobin (HGB) ≥90 g/L. 2. Absolute neutrophil count (NEUT) ≥1.5×10⁹/L. 3. Platelet count (PLT) ≥90×10⁹/L. 4. Total bilirubin (TBIL) ≤1.5×ULN. 5. Alanine aminotransferase (ALT) and Aspartate transferase (AST) ≤2.5×ULN. 6. Creatinine clearance (CCR) ≥50 mL/min. 7. Prothrombin time (PT), Activated partial thromboplastin time (APTT), and International Normalized Ratio (INR) ≤1.5×ULN (without anticoagulation therapy). 8. Serum albumin (ALB) ≥30 g/L (no albumin infusion within 7 days prior to screening). * For participants of childbearing potential: Agreement to use effective contraception during the study and for 6 months after study completion. Females must have a negative serum/urine pregnancy test within 7 days before enrollment; males must agree to effective contraception during and for 6 months post-study. Exclusion Criteria: * Patients with undifferentiated thyroid carcinoma or medullary thyroid carcinoma; * Patients who have had or currently have other malignancies. The following two situations are eligible for enrollment: other malignancies treated with a single surgery and achieving a disease - free survival (DFS) of 5 consecutive years; cured cervical carcinoma in situ, non - melanoma skin cancer, and superficial bladder tumors \[Ta (non - invasive tumor), Tis (carcinoma in situ), and T1 (tumor invading the basement membrane)\]. * Those with multiple factors affecting oral medications (such as difficulty in swallowing, chronic diarrhea, and intestinal obstruction, etc.); * Adverse reactions from previous treatments have not recovered to a Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. grade score ≤ 1, except for grade 2 alopecia, grade 2 peripheral neuropathy, grade 2 anemia, non - clinically significant and asymptomatic grade 2 laboratory abnormalities, and hypothyroidism stabilized by hormone replacement therapy, and other toxicities judged by the investigator to have no safety risks. * Known allergy to the excipient components of the study drug. * Subjects who have participated in and used other anti - tumor clinical trial drugs within 4 weeks before randomization. * As judged by the investigator, there are situations that seriously endanger the safety of the subject or affect the subject's completion of the study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06860971 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Thyroid Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06860971 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 144 participants.
Is NCT06860971 currently recruiting?
Yes, NCT06860971 is actively recruiting participants. Contact the research team at 3192279599@qq.com for enrollment information.
Where is the NCT06860971 trial being conducted?
This trial is being conducted at Hefei, China, Beijing, China, Chongqing, China, Fuzhou, China and 11 additional locations.
Who is sponsoring the NCT06860971 clinical trial?
NCT06860971 is sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. The trial plans to enroll 144 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.